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INTRODUCTION
Neopterin is an intermediate product of biopterin, a nerve
transmitter coenzyme. It is a pyrazino-pyrimidine compound,
synthesized by monocytes and macrophages as a result of stim-
ulation by endotoxin and interferon  in activated T cells.
Neopterin levels in body fluids are elevated in a variety of
diseases in which T cells or macrophages are activated (1, 2).
Therefore, neopterin levels can be useful for the evaluation
of disease activity and prognosis in a variety of conditions
(3-7).
Lin reported that increased urinary neopterin levels are
related to increases in interlukin-2 and the interferon  ob-
served in the membranous nephropathy associated with hep-
atitis B, which is generally accompanied by the nephrotic syn-
drome or severe proteinuria (3). He noted that neopterin is not
specific in this case, but it is clear that neopterin is useful in
the monitoring the clinical course, or even as a prognostic
marker. Several studies have reported that neopterin levels are
increased in serum or urine in the nephrotic syndrome, in
chronic and acute glomerulonephritis, and in chronic renal
disease (4-7). Fuchs et al. reported that neopterin levels were
increased in end-stage renal disease patients who had under-
gone hemodialysis for more than 1 yr (8). They attributed this
to various interactions between blood coagulation molecules
and the hemodialysis membrane, as well as to the activated
cellular immune response associated with exposure to the dial-
ysis membrane.
The purpose of our study was to determine whether serum
and urine neopterin levels were elevated in some renal diseases,
including nephrotic syndrome (NS), chronic renal failure
(CRF), and end-stage renal disease (ESRD). We also assessed
correlations between serum and urinary neopterin levels and
some of the clinical parameters seen in these conditions.
MATERIALS AND METHODS
Subjects
The study group was composed of 91 persons who were out-
patients or inpatients at the Kangbuk Samsung Hospital in
June 2002. This group included 19 NS patients whose dis-
eases had been proven by biopsy, 8 CRF patients with glome-
rular filtration rates of 10-60 mL/min/1.73 m2 and 64 ESRD
patients who had undergone maintenance hemodialysis for
more than 3 months. The pathologic diagnoses of the NS
patients included 11 patients with minimal-change nephrotic
syndrome, 4 with IgA nephropathy, 2 with membranous
glomerulonephritis, 1 with membrano-proliferative glomeru-
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The Clinical Significance of Serum and Urinary Neopterin Levels in
Several Renal Diseases
Neopterin is a pyrazino-pyrimidine compound, and is known to be a marker asso-
ciated with cell-mediated immunity in various diseases. We hypothesized that the
levels of serum and urine neopterin would be elevated in renal disease, and would
correlate with certain clinical parameters. We evaluated serum and urinary neopterin
levels in patients with several renal diseases, including nephrotic syndrome (NS,
n=19), chronic renal failure (CRF, n=8), end stage renal disease (ESRD, n=64) and
controls (n=22). Serum neopterin was elevated in patients with CRF and ESRD, as
compared to controls. Urinary neopterin levels were also found to be elevated in
patients with CRF and ESRD, as compared to controls. Serum neopterin levels show-
ed significant positive correlation with age, serum BUN and creatinine levels, and
inverse correlation with WBC, hemoglobin, hematocrit, serum albumin and total iron
binding capacity. Urine neopterin levels exhibited positive correlation with age and
serum creatinine levels, and inverse correlation with WBC, hemoglobin, hematocrit,
BUN and serum albumin. In conclusion, increased serum and urinary neopterin
levels were found in some patients with renal disease and were correlated with cer-
tain clinical parameters.
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lonephritis, and 1 case of focal segmental glomerulosclerosis.
The underlying causes of CRF included 6 cases of diabetes
mellitus, and 2 patients with severe hypertension. The under-
lying causes of ESRD included 44 cases of diabetes mellitus,
17 cases of hypertension, 1 with IgA nephropathy, 1 patient
with systemic lupus nephritis, and 1 with autosomal domi-
nant polycystic kidney disease. The controls were selected
in order to determine a normal range for neopterin. They
were 22 patients with GFR values of more than 90 mL/min/
1.73 m2. Control subjects had no renal disease, hepatic dis-
ease, infections, or autoimmune diseases (Table 1).
Methods
Serum neopterin was measured as follows: 3 mL of serum
was obtained from a clotted blood sample collected in a shad-
ed tube, as neopterin is sensitive to light. In ESRD patients,
blood samples were taken before hemodialysis. The tube was
maintained at 4℃. Serum and urinary neopterin levels were
measured by radioimmune assay (ICN Biomedicals, Costa
Mesa, California, U.S.A.) within 30 min, using a double anti-
body technique. In order to measure urinary neopterin levels,
100 mL of a first-void morning urine was collected from
patients who were able to urinate. The urine was kept in a
urine cup which was shaded and maintained at 4℃. The speci-
mens were then centrifuged for 10 min, and the supernatant
was separated. Creatinine levels were measured in the super-
nants, and the remaining urine was diluted with neopterin
urine buffer to concentrations of 1:50 and 1:500. The creati-
nine levels of the remaining urine were then measured. Neo-
pterines are excreted by the kidney, and therefore urine neo-
pterin levels were higher than serum neopterin levels. Uri-
nary neopterin levels are expressed per mole of creatinine so
as to standardize differences in renal function vs. neopterin
excretion.
Statistical analysis
Statistical analysis of the data was performed with SPSS
version 11.0 software, and continuous variables were presented
as means±standard deviation. Comparisons between each
renal disease group and the control group were carried out
using the Mann-Whitney test. The relationship between
serum and urinary neopterin levels and clinical parameters
was determined using the Spearman correlation analysis and
the linear regression method. p values of less than 0.05 were
considered to be statistically significant.
RESULTS
Serum neopterin
Serum neopterin levels were elevated in patients with NS
(14.1±30.9 ng/mL), CRF (28.2±19.4 ng/mL), and ESRD
(68.6±25.5 ng/mL) in comparison to control subjects (1.6
±0.3 ng/mL). Patients with CRF and ESRD, in particular,
exhibited statistically significant elevated levels of serum neo-
pterin compared to controls (p<0.05) (Fig. 1). 
Urine neopterin
Urinary neopterin levels were elevated in patients with NS
(203.2±349.6  M/M creatinine), CRF (319.2±107.7 M/
M creatinine) and ESRD (407.9±256.9 M/M  creatinine),
in comparison to controls (108.9±57.9 M/M  creatinine).
Patients with CRF and ESRD, in particular, exhibited sta-
tistically significant higher urine neopterin than control (p<
0.05) (Fig. 2).
The relationship between serum neopterin and other clin-
ical parameters
Serum neopterin levels were positively correlated with age, Control NS CRF ESRD
Number of patients 22 19 8 64
Age, yr (mean±S.D.) 47.2±11.9 38.6±31.9 58.3±8.9 57.1±13.5
Sex (male:female)  15:7 13:6 6:2 43:21
Underlying disease
DM 6 44
Hypertension 2 17
Others 2
Pathologic diagnosis  
MCNS 11
IgA nephropathy 4 1
MGN 2
MPGN 1
FSGS 1
Table 1. Demographic data of the patient population
NS, nephrotic syndrome; CRF, chronic renal failure; ESRD, end-stage
renal disease; DM, diabetes mellitus; MCNS, minimal change nephrotic
syndrome; MGN, membranous glomerulonephritis; MPGN, membrano-
proliferative glomerulonephritis; FSGS, focal segmental glomerulosclerosis. 
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Fig. 1. Levels of serum neopterin in patient population. 
NS, nephrotic syndrome; CRF, chronic renal failure; ESRD, end-
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BUN and serum creatinine levels. Serum neopterin levels
exhibited inverse correlation with WBC, hemoglobin, hemat-
ocrit, serum albumin and total iron binding capacity (Table 2). 
The relationship between urine neopterin and clinical
parameters
Urine neopterin levels exhibited a positive correlation with
age and serum creatinine levels (p<0.05). Urine neopterin
levels showed significant inverse correlation with WBC,
hemoglobin, hematocrit, BUN and serum albumin (p<0.05)
(Table 3).
DISCUSSION
Neopterin, which is a biochemical marker of cellular im-
mune response, belongs to the group of compounds known
as pteridines. Pteridines are pyrazino-(2,3-d-) pyrimidine
derivative compounds which are synthesized from guanosine
triphosphate. Neopterin is 253 daltons in size, twice the size
of creatinine (113 daltons). The first pteridines were initially
identified in 1889, and in 1979, Wachter et al. reported that
urine neopterin levels were elevated in cases of viral infections
and tumors (9). Recently, a marked abnormality in pteridine
metabolism has been noted in cases of chronic renal disease
(10). Neopterin is produced in monocytes and macrophages
as a result of stimulation by interferon  and endotoxin. The
mechanism underlying the generation of neopterin involves
the accumulation of precursor 7,8-dihydroneopterin triphos-
phate, due to deficiencies in 6-pyruvoyl tetrahydropterin
synthetase. This precursor is then converted to neopterin by
phosphatase. Neopterin is also associated with the activity
of T-lymphocytes, monocytes and macrophages, and it is
closely associated with the ability of these cells to break down
hydrogen peroxide (1, 2). 
In recent studies, increased serum and urinary neopterin
levels have been used as diagnostic or prognostic markers in
several conditions. These include: various immune-mediated
clinical conditions, including transplantation rejection (11);
hepatitis and other viral infections, such as human immun-
odeficiency virus and cytomegalovirus; bacterial infections
(3, 12, 13); autoimmune diseases such as systemic lupus ery-
thematosus and rheumatoid arthritis; tumors, such as hepa-
tocellular carcinoma, stomach cancer, or uroepithelial cancer
(14, 15); congestive heart failure; renal failure; coronary artery
disease; and, myocardial infarction. Weiss et al. reported that
neopterin is a marker for disease progression and complica-
tion in diabetes mellitus, such as glycation end-product pen-
tosidine, and other inflammatory molecules, such as inter-
leukin-6 and C-reactive protein (CRP) are (16). Murr et al.
reported that serum neopterin is closely related to the acti-
vation of immune mechanisms in anemia, weight loss, or
cachexia in malignant tumors or chronic disease, and is also
associated with interferon  and tumor necrosis factor- (17).
Therefore, increased neopterin levels are observed primarily
in diseases in which monocytes or macrophages have been
activated. Thus, they provide valuable information with regard
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Fig. 2. Levels of urine neopterin in patient population. 
NS, nephrotic syndrome; CRF, chronic renal failure; ESRD; end-
stage renal disease.
Serum neopterin
r p
Age 0.251 0.018 S
WBC -0.243 0.024 S
Hemoglobin -0.279 0.009 S
Hematocrit -0.244 0.023 S
BUN 0.405 <0.0001 S
Creatinine 0.562 <0.0001 S
Total protein 0.104 0.366 NS
Albumin -0.123 0.261 S
Triglyceride -0.068 0.535 NS
Iron -0.100 0.434 NS
TIBC -0.394 0.001 S
Table 2. Correlation between serum neopterin and clinical para-
meters
TIBC, total iron binding capacity; r, regression coefficient; S, statistically
significant defined by p<0.05; NS, statistically non-significant defined
by p≥0.05.
Urine neopterin
r p
Age 0.434 0.007 S
WBC -0.409 0.013 S
Hemoglobin -0.646 <0.0001 S
Hematocrit -0.660 <0.0001 S
BUN -0.611 <0.0001 S
Serum creatinine 0.522 0.001 S
Total serum protein 0.104 0.366 NS
Serum albumin -0.607 <0.0001 S
Triglyceride -0.235 0.181 NS
Table 3. Correlation between urine neopterin and clinical para-
meters
r, regression coefficient; S, statistically significant defined by p<0.05;
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to cellular immunity, acting not only as an initial inflamma-
tory marker, but also as a predictive factor for the progression
of disease. In our study, we did not measure CRP or cytokines
such as interleukin-6, interferon  and tumor necrosis fac-
tor- . However, serum neopterin had an inverse correlation
with other proteins that decline in the presence of inflamma-
tion, such as albumin and total iron binding capacity.
In our study, serum and urine neopterin levels were increased
in patients with CRF and ESRD. Serum neopterin levels show-
ed a positive correlation with serum creatinine levels. These
results are consistent with the report of Godai et al., in that
serum neopterin levels have a positive relationship with cre-
atinine, and a negative relationship with creatinine clearance
(4). Pecoits-Filho et al. also reported that neopterin levels were
significantly higher in the subgroup of patients with a low
glomerular filtration rate, suggesting either impaired renal
elimination, increased generation in uremia, or an adverse
effect of inflammation on renal function (18). In our study,
there was a trend towards increased serum and urine neopterin
levels in patients with NS compared to the control group,
but it was not statistically significant. The standard devia-
tion of serum and urinary neopterin levels in patients with
NS was greater than in patients with other renal diseases. Oda
et al. reported that in patients with steroid-responsive neph-
rotic syndrome, elevated neopterin levels decreased after steroid
treatment. However, in a steroid-resistant group, neopterin
levels increased significantly. They suggested that steroid ther-
apy may decrease increased neopterin production by normaliz-
ing disturbed T-cell function (7).
Serum neopterin varies in response to monocyte and macro-
phage activation, according to increases in the immune res-
ponse. Activation of monocytes and macrophages results in
iron deficiency, due to the utilization of iron by the blood.
Iron deficiency stimulates increased neopterin release, and
neopterin aggravates anemia via the indirect inhibition of
hematopoiesis. Berdowska et al. reported that serum neopterin
levels are inversely related to iron, transferrin, and hemoglobin,
and are positively related to levels of ferritin, which functions
as an intracellular iron carrier (19). In our study, serum neo-
pterin levels were also inversely related to hemoglobin levels
and the total iron binding capacity. Anemia treatment in
patients with CRF and ESRD may have some influence on
our results. 
The present study has several limitations. Our study did
not directly relate serum and urinary neopterin levels with
observed monocyte or macrophage activation. Also, we were
not sure of the validity of urinary neopterin or creatinine in
patients with ESRD, since these patients are mostly oliguric.
In conclusion, serum and urinary neopterin levels were ele-
vated in patients with certain renal diseases. In addition, neo-
pterin levels were correlated with some clinical parameters
in those patients. We suggest that serum and urinary neopterin
levels may be useful marker for predicting disease activity
and prognosis in some patients with renal disease. This should
be confirmed by a prospective long term study in a larger
group of patients. 
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